Entra Dry Syrup
Entra Dry binds to 1 or more of the penicillin-binding proteins (PBPs) which inhibit the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death.
Entra Dry is used for the treatment of Community Acquired Pneumonia, Acute Exacerbation of Chronic Bronchitis, Acute Maxillary Sinusitis, Pharyngitis, Tonsillitis, Uncomplicated Skin and Skin Structure, Infections
Entra Dry is also used to associated treatment for these conditions: Acute Exacerbation of Chronic Bronchitis (AECB), Acute Exacerbation of Chronic Bronchitis caused by Haemophilus Influenza, Acute Exacerbation of Chronic Bronchitis caused by Streptococcus Pneumoniae, Acute exacerbation of chronic bronchitis caused by Haemophilus parainfluenzae, Acute exacerbation of chronic bronchitis caused by Moraxella catarrhalis, Acute maxillary sinusitis, Acute maxillary sinusitis caused by H. influenzae, Acute maxillary sinusitis caused by M. catarrhalis, Acute maxillary sinusitis caused by Susceptible strains of Streptococcus pneumoniae, Community Acquired Pneumonia (CAP), Community acquired pneumonia caused by Susceptible strains of Streptococcus pneumoniae, Pneumonia due to Haemophilus influenzae (H. influenzae), Streptococcal Pharyngitis, Streptococcal tonsillitis, Tonsillitis, Uncomplicated Skin and Skin Structure Infections, Uncomplicated skin and skin structure infections caused by streptococcus pyogenes, staphylococcus aureus, Acute otitis media caused by M. catarrhalis, Acute otitis media caused by S.pneumoniae, Bacterial otitis media caused by Haemophilus influenzae, Community aquired pneumonia caused by H. parainfluenzae, Community aquired pneumonia caused by M.catarrhalis
|Trade Name||Entra Dry|
|Cefdinir Other Names||Cefdinir, Cefdinirum, CFDN|
The plasma protein binding of cefdinir ranges from 60% to approximately 70%.
|Therapeutic Class||Third generation Cephalosporins|
|Last Updated:||June 23, 2021 at 9:00 am|
Entra Dry dosage
Adult: 600 mg daily as a single or in 2 divided doses for 5-10 days.
Child: ≥6 months: 14 mg/kg daily as a single or in 2 divided doses. Max: 600 mg daily.
Common side effects are Diarrhea, Vaginal moniliasis, Nausea & Vomiting, Headache, Rash etc.
Entra Dry, as with other broad-spectrum antibiotics, should be prescribed with caution in individuals with a history of colitis. In patients with transient or persistent renal insufficiency (creatinine clearance <30 ml/min), the total daily dose of Entra Dry should be reduced.
Antacids: Entra Dry should be taken at least 2 hours interval of antacid administration.
Iron supplement: Entra Dry should be taken at least 2 hours interval of iron supplement administration.
Probencid: It inhibits the renal excretion of cefdinir.
- Avoid multivalent ions. Do not take aluminum, magnesium, or iron containing products up to 2 hours before or after this medication.
- Take with or without food. The absorption is unaffected by food.
Volume of Distribution
The average volume of distribution of cefdinir in adults is about 0.35 L/kg and 0.67 L/kg in children. Another resource estimates the volume of distribution in adults at 1.56–2.09 L/kg. Entra Dry is found to be distributed in various tissues at clinically effective concentrations. It may be found in the epithelial lining fluid, bronchial mucosa, tonsils, sinuses, skin blister fluid, as well as the middle ear fluid. Third-generation cephalosporins such as cefdinir cross the blood-brain barrier and are found in high concentrations in the cerebrospinal fluid, unlike their first and second generation counterparts. The wide tissue distribution of cefdinir allows it to treat a variety of infections throughout the body.
The average plasma elimination half-life is about 1.7 hours in adults. In children and healthy infants, plasma elimination half-life ranges from 1.2–1.5 hours.
The renal clearance in healthy adults in a pharmacokinetic study was 2.0 (± 1.0) mL/min/kg and the clearance in patients with renal failure was lower, decreasing in proportion to the degree of renal impairment. Dose adjustment is required in patients with renal impairment.
Pregnancy & Breastfeeding use
Pregnancy Category B. There are no adequate and well-controlled studies in pregnant women. This drug should be used during pregnancy only if clearly needed. Following administration of single 600 mg doses, Entra Dry was not detected in human breast milk.
Entra Dry is contraindicated in patients with known allergy to the cephalosporin class of antibiotics.
Symptoms: Nausea, vomiting, epigastric distress, diarrhoea, convulsions.
Management: Haemodialysis may be useful in the event of a serious toxic reaction particularly if renal function is compromised.
Store between 20-25° C.